These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31598491)

  • 21. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Tanaka S; Matsunami N; Morishima H; Oda N; Takashima T; Noda S; Kashiwagi S; Tauchi Y; Asano Y; Kimura K; Fujioka H; Terasawa R; Kawaguchi K; Ikari A; Morimoto T; Michishita S; Kobayashi T; Sakane J; Nitta T; Sato N; Hokimoto N; Nishida Y; Iwamoto M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1099-1104. PubMed ID: 30963212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients].
    Zhou YJ; Ying M; He YJ; Liu YQ; Fan ZQ; Fan T; Li JF; Wang TF; Xie YT; Lu AP; Ouyang T
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1711-5. PubMed ID: 24124677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
    Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
    Candelaria RP; Bassett RL; Symmans WF; Ramineni M; Moulder SL; Kuerer HM; Thompson AM; Yang WT
    Oncologist; 2017 Apr; 22(4):394-401. PubMed ID: 28314842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.
    Kolberg HC; Akpolat-Basci L; Stephanou M; Aktas B; Hannig CV; Liedtke C
    Breast Care (Basel); 2016 Oct; 11(5):323-327. PubMed ID: 27920624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.